{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=17",
    "query": {
      "condition": "Recurrent",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 9639,
    "total_pages": 964,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T14:59:51.492Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01497444",
      "title": "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "hypoxia-activated prodrug TH-302",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-05",
      "completion_date": "2019-11-01",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497444"
    },
    {
      "nct_id": "NCT00036764",
      "title": "BMS-247550 in Treating Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2002-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036764"
    },
    {
      "nct_id": "NCT00306787",
      "title": "Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "Famciclovir",
          "type": "DRUG"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching famciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1179,
      "start_date": "2006-03",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00306787"
    },
    {
      "nct_id": "NCT04125238",
      "title": "Increasing the Temporal Window in Individuals With Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Episodic Future Thinking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Episodic Thinking",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 154,
      "start_date": "2020-11-13",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04125238"
    },
    {
      "nct_id": "NCT00940316",
      "title": "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "panitumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2010-01-18",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 10,
      "location_summary": "Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more",
      "locations": [
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        },
        {
          "city": "Terre Haute",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940316"
    },
    {
      "nct_id": "NCT00003404",
      "title": "Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Adjuvant Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 46,
      "start_date": "1998-01",
      "completion_date": "2008-11-17",
      "has_results": true,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003404"
    },
    {
      "nct_id": "NCT04080284",
      "title": "Trial of Maintenance With Niraparib- Uterine Serous Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Papillary Serous Endometrial Carcinoma",
        "Uterine Serous Carcinoma",
        "Endometrial Carcinoma",
        "Cancer of the Endometrium"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2019-12-30",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 6,
      "location_summary": "New Brunswick, New Jersey • Newark, New Jersey • Bay Shore, New York + 3 more",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Bay Shore",
          "state": "New York"
        },
        {
          "city": "Greenlawn",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080284"
    },
    {
      "nct_id": "NCT00006247",
      "title": "SU5416 in Treating Children With Recurrent or Progressive Brain Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "semaxanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 33,
      "start_date": "2000-08",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2009-10-14",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006247"
    },
    {
      "nct_id": "NCT03664726",
      "title": "MINDD 3: Prediabetes and Delay Discounting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PreDiabetes"
      ],
      "interventions": [
        {
          "name": "Episodic Future Thinking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Episodic Recent Thinking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Scarcity Narrative",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Neutral Narrative",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Leonard Epstein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2018-02-12",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Roanoke, Virginia",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03664726"
    },
    {
      "nct_id": "NCT04074785",
      "title": "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "GBM",
        "Glioblastoma",
        "Brain Tumor",
        "Brain Tumor, Recurrent"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-12-13",
      "completion_date": "2023-10-16",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-10-17T14:59:51.492Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04074785"
    }
  ]
}